Research analysts at Cantor Fitzgerald started coverage on shares of eFFECTOR Therapeutics (NASDAQ:EFTR) in a research note issued on Monday, PriceTargets.com reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 140.85% from the company’s current price.
Shares of EFTR stock opened at $20.76 on Monday. eFFECTOR Therapeutics has a 52 week low of $8.33 and a 52 week high of $40.42.
eFFECTOR Therapeutics Company Profile
Featured Article: Green Investing
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.